Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€64.50

€64.50

-
-
-
€100.71
 
04.07.25 / Frankfurt WKN: 881782 / Symbol: HAE / Name: Haemonetics / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Haemonetics Corp. Stock

With 15 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 100 € there is a hugely positive potential of 55.04% for Haemonetics Corp. compared to the current price of 64.5 €.

Pros and Cons of Haemonetics Corp. in the next few years

Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Haemonetics Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Haemonetics Corp. - 4.032% 4.878% -16.774% -14.570% 0.781% -20.370%
Bio-Rad Labs Inc. A -0.280% 1.679% 9.142% -14.453% -32.537% -57.001% -48.568%
Neogen Corp. -1.320% 11.881% -1.310% -67.943% -62.333% - -
Merit Medical Systems 0.000% -0.637% -4.878% 0.000% -14.754% 51.456% 93.069%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-12

Haemonetics Corporation (HAE) from the Healthcare Equipment and Supplies industry have shown considerable growth in their financials over the past few years. At first glance, the company's financial performance seems to be on an upward trajectory, demonstrating a consistent increase in total assets, revenue, and net income.

Rising total assets: Haemonetics' total assets have grown from $1.267 billion in 2020 to $1.879 billion in 2022, which signifies approximately a 48% increase over the span of two years. The growth of total assets is a positive indication of the company's financial health and suggests an expanding business.

Steady growth in net income: The company's net income has grown consistently over the years, from $76.5 million in 2020 to $43.4 million in 2022. This growth is indicative of a healthier profit margin and effective cost management by the company.

Comments

Haemonetics Corporation (NYSE: HAE) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Ratings data for HAE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 3.20%
Target price 74.437
Change
Ends at 26.06.26

Haemonetics Corporation (NYSE: HAE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $87.00 price target on the stock.
Ratings data for HAE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 7.50%
Target price 93.629
Change
Ends at 09.05.26

Haemonetics Co. (NYSE: HAE) had its "strong-buy" rating re-affirmed by analysts at Raymond James. They now have a $105.00 price target on the stock, down previously from $115.00.
Ratings data for HAE provided by MarketBeat
Show more